Skip to main content

Table 4 Clinical endpoints modelled and utility decrements applied

From: Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Health state

Utility

Source

Ischaemic Heart Disease

-0.09

UKPDS Study No.68[16]

Myocardial Infarction

-0.055

UKPDS Study No.68[16]

Congestive Heart Failure

-0.108

UKPDS Study No.68[16]

Stroke

-0.164

UKPDS Study No.68[16]

Blindness in one eye

-0.074

UKPDS Study No.68[16]

ESRD

-0.305

Lee et al. [42]

Amputation

-0.28

UKPDS Study No.68[16]